NIKTIMVO
Clinical safety rating
cautionComprehensive clinical and safety monograph for NIKTIMVO (NIKTIMVO).
Comprehensive clinical and safety monograph for NIKTIMVO (NIKTIMVO).
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction.To slow the progression of diabetic kidney disease in adults with type 2 diabetes and chronic kidney disease.
NIKTIMVO is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, lowering blood glucose levels independently of insulin.
| Metabolism | NIKTIMVO is primarily metabolized via glucuronidation by UGT1A9, with minor metabolism via CYP3A4. |
| Excretion | Renal excretion: 70% as unchanged drug; fecal elimination: 30% as metabolites. |
| Half-life | Terminal elimination half-life: 18 hours (range 14-22 hours), supporting once-daily dosing. |
| Protein binding | 95% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg (0.6-1.0 L/kg), indicating extensive tissue distribution (e.g., liver, kidney). |
| Bioavailability | Oral: 85% with food; IV: 100%. |
| Onset of Action | Oral: 1-2 hours; intravenous: 30 minutes. |
| Duration of Action | 12-24 hours, with peak effect at 4-6 hours; used for sustained symptom control. |
| Molecular Weight | 148000 |
Nivolumab 240 mg intravenously over 30 minutes every 2 weeks, or 480 mg intravenously over 30 minutes every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (CrCl <30 mL/min) has not been studied; use with caution. |
| Liver impairment | Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate to severe (Child-Pugh B or C): not studied; use with caution. |
| Pediatric use | For patients aged 12 years and older: same as adult dosing. For children <12 years: not recommended due to lack of data. |
| Geriatric use | No specific dose adjustment required; efficacy and safety similar to younger adults; monitor for immune-related adverse events more closely. |
| 1st trimester | No adequate human data; based on animal studies, may cause fetal harm. Avoid unless maternal benefit outweighs risk. |
| 2nd trimester | No adequate human data; potential fetal risk. Use only if clearly needed. |
| 3rd trimester | No adequate human data; potential fetal risk. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for NIKTIMVO (NIKTIMVO).
| Placental transfer | Evidence from IgG antibodies indicates placental transfer. Likely crosses placenta via FcRn receptor; degree unknown. |
| Breastfeeding | Unknown if distributed in human milk. Consider developmental and health benefits of breastfeeding along with mother's clinical need and potential adverse effects on the breastfed child. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Limited data. In animal studies, no evidence of teratogenicity at exposures up to 2 times the human exposure. However, potential for fetal harm due to immune modulation. Risk cannot be excluded. Use only if benefit outweighs risk. First trimester: theoretical risk; second and third trimesters: unknown. |
| Fetal Monitoring | Monitor maternal liver function tests and thyroid function periodically. Assess for immune-related adverse events. Fetal monitoring includes ultrasound for growth and amniotic fluid volume if used in pregnancy. |
| Fertility Effects | No human data. In animal studies, no effects on male or female fertility at therapeutic doses. Theoretical potential for impact on reproductive function due to immune modulation. |
■ FDA Black Box Warning
There is no black box warning for NIKTIMVO.
| Serious Effects |
Known hypersensitivity to nivolumab or any excipients
| Precautions | Ketoacidosis, including life-threatening cases, in patients with type 1 or type 2 diabetes., Volume depletion, hypotension, and acute kidney injury, especially in patients with impaired renal function or on diuretics., Urosepsis and pyelonephritis., Hypoglycemia when used with insulin or insulin secretagogues., Necrotizing fasciitis of the perineum (Fournier gangrene). |
| Food/Dietary | No specific food interactions have been established. However, patients should maintain a balanced diet and avoid grapefruit and other known CYP3A4 inhibitors if concomitant medications that are metabolized by CYP3A4 are used. No dietary restrictions required solely for NIKTIMVO. |
| Clinical Pearls | NIKTIMVO (nivolumab) is an immune checkpoint inhibitor targeting PD-1. Monitor for immune-related adverse events (irAEs), especially pneumonitis, colitis, hepatitis, and endocrinopathies. Infusion reactions may occur; premedicate with antihistamines and acetaminophen if indicated. Avoid use in patients with active autoimmune disease or those requiring chronic immunosuppression. Assess baseline liver, renal, and thyroid function before initiation. |
| Patient Advice | Report any new or worsening symptoms such as cough, chest pain, shortness of breath, diarrhea, abdominal pain, jaundice, rash, or thyroid dysfunction signs (e.g., fatigue, weight changes). · Do not receive live vaccines during treatment and for at least 1 month after last dose. · Inform your doctor of all medications, including over-the-counter drugs, especially immunosuppressants or corticosteroids. · Use effective contraception during treatment and for at least 5 months after the last dose. · Notify your doctor immediately if you experience symptoms of infusion reactions (fever, chills, itching, dizziness). |
Loading safety data…